HomeCompareTRUMF vs ABBV

TRUMF vs ABBV: Dividend Comparison 2026

TRUMF yields 1.42% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRUMF wins by $513.9K in total portfolio value· pulled ahead in Year 7
10 years
TRUMF
TRUMF
● Live price
1.42%
Share price
$12.38
Annual div
$0.18
5Y div CAGR
75.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$616.2K
Annual income
$410,809.26
Full TRUMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TRUMF vs ABBV

📍 TRUMF pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRUMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRUMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRUMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRUMF
Annual income on $10K today (after 15% tax)
$120.65/yr
After 10yr DRIP, annual income (after tax)
$349,187.87/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TRUMF beats the other by $328,131.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRUMF + ABBV for your $10,000?

TRUMF: 50%ABBV: 50%
100% ABBV50/50100% TRUMF
Portfolio after 10yr
$359.3K
Annual income
$217,790.51/yr
Blended yield
60.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TRUMF
No analyst data
Altman Z
4.0
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRUMF buys
0
ABBV buys
0
No recent congressional trades found for TRUMF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRUMFABBV
Forward yield1.42%3.06%
Annual dividend / share$0.18$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR75.5%40.6%
Portfolio after 10y$616.2K$102.3K
Annual income after 10y$410,809.26$24,771.77
Total dividends collected$576.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRUMF vs ABBV ($10,000, DRIP)

YearTRUMF PortfolioTRUMF Income/yrABBV PortfolioABBV Income/yrGap
1$10,949$249.12$11,550$430.00$601.00ABBV
2$12,163$447.38$13,472$627.96$1.3KABBV
3$13,829$815.13$15,906$926.08$2.1KABBV
4$16,318$1,520.16$19,071$1,382.55$2.8KABBV
5$20,402$2,941.94$23,302$2,095.81$2.9KABBV
6$27,863$6,033.08$29,150$3,237.93$1.3KABBV
7← crossover$43,328$13,514.24$37,536$5,121.41+$5.8KTRUMF
8$80,829$34,468.45$50,079$8,338.38+$30.8KTRUMF
9$191,954$105,467.10$69,753$14,065.80+$122.2KTRUMF
10$616,200$410,809.26$102,337$24,771.77+$513.9KTRUMF

TRUMF vs ABBV: Complete Analysis 2026

TRUMFStock

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

Full TRUMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TRUMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRUMF vs SCHDTRUMF vs JEPITRUMF vs OTRUMF vs KOTRUMF vs MAINTRUMF vs JNJTRUMF vs MRKTRUMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.